Cullinan Therapeutics News

Express News | Cullinan Therapeutics Files For Resale Of Up To 14.4M Shares By The Selling Stockholders

BenzingaMay 16 16:45 ET

Express News | Cullinan Therapeutics Inc Files for Resale of up to 14.4 Mln Shares by the Selling Stockholders - SEC Filing

ReutersMay 16 16:12 ET

Express News | Cullinan Therapeutics Shares Are Trading Lower After the Company Reported Q1 Results and Provided a Corporate Update

BenzingaMay 16 15:20 ET

HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating

Cullinan Oncology (CGEM) has an average buy rating and a price target range of $28 to $40, according to analysts polled by Capital IQ. Price: 25.23, Change: -1.49, Percent Change: -5.58

MT NewswiresMay 16 12:03 ET

Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.

Cullinan Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 16 12:00 ET

Express News | Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target

BenzingaMay 16 08:22 ET

Express News | Cullinan Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $28 From $29

ReutersMay 16 06:00 ET

Cullinan Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 22:44 ET · Announcements

Express News | Cullinan Therapeutics Inc: Qtrly Shr Loss $0.86

ReutersMay 15 16:09 ET

Express News | Cullinan Therapeutics: Cash & Investments as of March 31, Plus Gross Proceeds of $280 Mln From April Private Placement Extends Cash Runway Into 2028

ReutersMay 15 16:08 ET

Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM

Cullinan Therapeutics 1Q Loss/Shr 86c >CGEM

Dow JonesMay 15 16:06 ET

Express News | Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

ReutersMay 15 16:05 ET

Press Release: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster s

Dow JonesMay 15 16:05 ET

Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing

Jennifer Michaelson, Chief Scientific Officer, on May 06, 2024, sold 63,606 shares in Cullinan Therapeutics (CGEM) for $1,796,676. Following the Form 4 filing with the SEC, Michaelson has control over

MT NewswiresMay 9 03:20 ET

Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...

Yahoo FinanceMay 9 03:09 ET

Cullinan Therapeutics(CGEM.US) Officer Sells US$1.8 Million in Common Stock

$Cullinan Therapeutics(CGEM.US)$ Officer Michaelson Jennifer sold 63,606 shares of common stock on May 6, 7, 2024 at an average price of $28.25 for a total value of $1.8 million.Source: Announcement W

moomoo NewsMay 8 20:13 ET

Investor Sentiment Swings in Favor of Cullinan Therapeutics (NASDAQ:CGEM)

TipRanksMay 2 04:42 ET

Express News | Cullinan Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $40

ReutersMay 1 07:00 ET

Cullinan Oncology Initiated at Buy by Stifel

Cullinan Oncology Initiated at Buy by Stifel

Dow JonesMay 1 05:59 ET

Express News | Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

BenzingaMay 1 05:49 ET